Drug Type Bispecific antibody |
Synonyms MEDI 7352 |
Target |
Mechanism NGF inhibitors(Nerve growth factor inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 2 | DK | 02 Dec 2020 | |
Osteoarthritis, Knee | Phase 2 | EE | 02 Dec 2020 | |
Osteoarthritis, Knee | Phase 2 | DE | 02 Dec 2020 | |
Osteoarthritis, Knee | Phase 2 | PL | 02 Dec 2020 | |
Osteoarthritis, Knee | Phase 2 | ZA | 02 Dec 2020 | |
Osteoarthritis, Knee | Phase 2 | ES | 02 Dec 2020 | |
Osteoarthritis, Knee | Phase 2 | GB | 02 Dec 2020 | |
Diabetic Neuropathies | Phase 2 | DK | 19 Nov 2018 | |
Diabetic Neuropathies | Phase 2 | HU | 19 Nov 2018 | |
Diabetic Neuropathies | Phase 2 | PL | 19 Nov 2018 |